Skip to content
Search

Latest Stories

Stokes has second finger operation, may miss Ashes

Stokes has second finger operation, may miss Ashes

Allrounder Ben Stokes looks set to miss the Ashes series against Australia later this year after England's cricket board (ECB) said on Thursday (7) he has undergone a second operation on a broken index finger.

The 30-year-old sustained the injury playing in the Indian Premier League in April and after the first operation he returned in July, leading England to a 3-0 one-day international series win over Pakistan despite needing injections to play.


Stokes then decided to take an indefinite break from cricket to focus on his mental health after pulling out of the home Test series against India that began in August.

"Stokes had two screws and scar tissue removed from the index finger of his left hand," the ECB said in a statement.

"He will now undergo an intensive period of rehabilitation for the next four weeks under the supervision of the ECB's medical team."

Stokes has been omitted from England's squad for the Twenty20 World Cup in the United Arab Emirates and Oman, and now looks likely to miss his second Ashes series.

He was ruled out of the 2017-18 tour after an incident at a Bristol nightclub.

The first match of the five-Test series against Australia is due to start on Dec. 8.

British media reported that skipper Joe Root confirmed his participation in the series and will likely be joined by a full-strength squad despite players having voiced their hesitancy over touring in a Covid-19 "bubble".

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less